GCP II inhibition rescues neurons from gp120IIIB-induced neurotoxicity

Ajit G. Thomas, Amos Bodner, Ghanashyam Ghadge, Raymond P. Roos, Barbara Slusher

Research output: Contribution to journalArticle

Abstract

Excessive glutamate neurotransmission has been implicated in neuronal injury in many disorders of the central nervous system (CNS), including human immunodeficiency virus (HIV)-associated dementia. Gp120IIIB is a strain of a HIV glycoprotein with specificity for the CXCR4 receptor that induces neuronal apoptosis in in vitro models of acquired immunodeficiency syndrome (AIDS)-induced neurodegeneration. Since the catabolism of the neuropeptide N-acetylaspartylglutamate (NAAG) by glutamate carboxypeptidase (GCP) II increases cellular glutamate, an event associated with excitotoxicity, we hypothesized that inhibition of GCP II may prevent gp120IIIB-induced cell death. Furthermore, through GCP II inhibition, increased NAAG may be neuroprotective via its agonist effects at the mGlu3 receptor. To ascertain the therapeutic potential of GCP II inhibitors, embryonic day 17 hippocampal cultures were exposed to gp120IIIB in the presence of a potent and highly selective GCP II inhibitor, 2-(phosphonomethyl)-pentanedioic acid (2-PMPA). 2-PMPA was found to abrogate gp120IIIB-induced toxicity in a dose-dependent manner. Additionally, 2-PMPA was neuroprotective when applied up to 2 h after the application of gp120IIIB. The abrogation of apoptosis by 2-PMPA was reversed with administration of mGlu3 receptor antagonists and with antibodies to transforming growth factor (TGF)-β. Further, consistent with the localization of GCP II, 2-PMPA failed to provide neuroprotection in the absence of glia. GCP II activity and its inhibition by 2-PMPA were confirmed in the hippocampal cultures using radiolabeled NAAG and high-performance liquid chromatography (HPLC) analysis. Taken together, these data suggest that GCP II is involved in mediating gp120-induced apoptosis in hippocampal neurons and GCP II inhibitors may have potential in the treatment of neuronal injury related to AIDS.

Original languageEnglish (US)
Pages (from-to)449-457
Number of pages9
JournalJournal of NeuroVirology
Volume15
Issue number5-6
DOIs
StatePublished - Dec 12 2009

Fingerprint

Glutamate Carboxypeptidase II
Neurons
Apoptosis
Glutamic Acid
Acquired Immunodeficiency Syndrome
HIV
CXCR4 Receptors
Inhibition (Psychology)
Central Nervous System Diseases
Wounds and Injuries
Transforming Growth Factors
Neuropeptides
Synaptic Transmission
Neuroglia
Dementia
2-(phosphonomethyl)pentanedioic acid
Glycoproteins
Cell Death

Keywords

  • GCP II
  • Glutamate
  • HIV-associated dementia
  • Metabotropic glutamate receptors
  • NAAG;TGF-β

ASJC Scopus subject areas

  • Virology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Neurology

Cite this

GCP II inhibition rescues neurons from gp120IIIB-induced neurotoxicity. / Thomas, Ajit G.; Bodner, Amos; Ghadge, Ghanashyam; Roos, Raymond P.; Slusher, Barbara.

In: Journal of NeuroVirology, Vol. 15, No. 5-6, 12.12.2009, p. 449-457.

Research output: Contribution to journalArticle

Thomas, Ajit G. ; Bodner, Amos ; Ghadge, Ghanashyam ; Roos, Raymond P. ; Slusher, Barbara. / GCP II inhibition rescues neurons from gp120IIIB-induced neurotoxicity. In: Journal of NeuroVirology. 2009 ; Vol. 15, No. 5-6. pp. 449-457.
@article{db910f66440b4b2fbfae5f1ca0d25c97,
title = "GCP II inhibition rescues neurons from gp120IIIB-induced neurotoxicity",
abstract = "Excessive glutamate neurotransmission has been implicated in neuronal injury in many disorders of the central nervous system (CNS), including human immunodeficiency virus (HIV)-associated dementia. Gp120IIIB is a strain of a HIV glycoprotein with specificity for the CXCR4 receptor that induces neuronal apoptosis in in vitro models of acquired immunodeficiency syndrome (AIDS)-induced neurodegeneration. Since the catabolism of the neuropeptide N-acetylaspartylglutamate (NAAG) by glutamate carboxypeptidase (GCP) II increases cellular glutamate, an event associated with excitotoxicity, we hypothesized that inhibition of GCP II may prevent gp120IIIB-induced cell death. Furthermore, through GCP II inhibition, increased NAAG may be neuroprotective via its agonist effects at the mGlu3 receptor. To ascertain the therapeutic potential of GCP II inhibitors, embryonic day 17 hippocampal cultures were exposed to gp120IIIB in the presence of a potent and highly selective GCP II inhibitor, 2-(phosphonomethyl)-pentanedioic acid (2-PMPA). 2-PMPA was found to abrogate gp120IIIB-induced toxicity in a dose-dependent manner. Additionally, 2-PMPA was neuroprotective when applied up to 2 h after the application of gp120IIIB. The abrogation of apoptosis by 2-PMPA was reversed with administration of mGlu3 receptor antagonists and with antibodies to transforming growth factor (TGF)-β. Further, consistent with the localization of GCP II, 2-PMPA failed to provide neuroprotection in the absence of glia. GCP II activity and its inhibition by 2-PMPA were confirmed in the hippocampal cultures using radiolabeled NAAG and high-performance liquid chromatography (HPLC) analysis. Taken together, these data suggest that GCP II is involved in mediating gp120-induced apoptosis in hippocampal neurons and GCP II inhibitors may have potential in the treatment of neuronal injury related to AIDS.",
keywords = "GCP II, Glutamate, HIV-associated dementia, Metabotropic glutamate receptors, NAAG;TGF-β",
author = "Thomas, {Ajit G.} and Amos Bodner and Ghanashyam Ghadge and Roos, {Raymond P.} and Barbara Slusher",
year = "2009",
month = "12",
day = "12",
doi = "10.3109/13550280903350598",
language = "English (US)",
volume = "15",
pages = "449--457",
journal = "Journal of NeuroVirology",
issn = "1355-0284",
publisher = "Springer New York",
number = "5-6",

}

TY - JOUR

T1 - GCP II inhibition rescues neurons from gp120IIIB-induced neurotoxicity

AU - Thomas, Ajit G.

AU - Bodner, Amos

AU - Ghadge, Ghanashyam

AU - Roos, Raymond P.

AU - Slusher, Barbara

PY - 2009/12/12

Y1 - 2009/12/12

N2 - Excessive glutamate neurotransmission has been implicated in neuronal injury in many disorders of the central nervous system (CNS), including human immunodeficiency virus (HIV)-associated dementia. Gp120IIIB is a strain of a HIV glycoprotein with specificity for the CXCR4 receptor that induces neuronal apoptosis in in vitro models of acquired immunodeficiency syndrome (AIDS)-induced neurodegeneration. Since the catabolism of the neuropeptide N-acetylaspartylglutamate (NAAG) by glutamate carboxypeptidase (GCP) II increases cellular glutamate, an event associated with excitotoxicity, we hypothesized that inhibition of GCP II may prevent gp120IIIB-induced cell death. Furthermore, through GCP II inhibition, increased NAAG may be neuroprotective via its agonist effects at the mGlu3 receptor. To ascertain the therapeutic potential of GCP II inhibitors, embryonic day 17 hippocampal cultures were exposed to gp120IIIB in the presence of a potent and highly selective GCP II inhibitor, 2-(phosphonomethyl)-pentanedioic acid (2-PMPA). 2-PMPA was found to abrogate gp120IIIB-induced toxicity in a dose-dependent manner. Additionally, 2-PMPA was neuroprotective when applied up to 2 h after the application of gp120IIIB. The abrogation of apoptosis by 2-PMPA was reversed with administration of mGlu3 receptor antagonists and with antibodies to transforming growth factor (TGF)-β. Further, consistent with the localization of GCP II, 2-PMPA failed to provide neuroprotection in the absence of glia. GCP II activity and its inhibition by 2-PMPA were confirmed in the hippocampal cultures using radiolabeled NAAG and high-performance liquid chromatography (HPLC) analysis. Taken together, these data suggest that GCP II is involved in mediating gp120-induced apoptosis in hippocampal neurons and GCP II inhibitors may have potential in the treatment of neuronal injury related to AIDS.

AB - Excessive glutamate neurotransmission has been implicated in neuronal injury in many disorders of the central nervous system (CNS), including human immunodeficiency virus (HIV)-associated dementia. Gp120IIIB is a strain of a HIV glycoprotein with specificity for the CXCR4 receptor that induces neuronal apoptosis in in vitro models of acquired immunodeficiency syndrome (AIDS)-induced neurodegeneration. Since the catabolism of the neuropeptide N-acetylaspartylglutamate (NAAG) by glutamate carboxypeptidase (GCP) II increases cellular glutamate, an event associated with excitotoxicity, we hypothesized that inhibition of GCP II may prevent gp120IIIB-induced cell death. Furthermore, through GCP II inhibition, increased NAAG may be neuroprotective via its agonist effects at the mGlu3 receptor. To ascertain the therapeutic potential of GCP II inhibitors, embryonic day 17 hippocampal cultures were exposed to gp120IIIB in the presence of a potent and highly selective GCP II inhibitor, 2-(phosphonomethyl)-pentanedioic acid (2-PMPA). 2-PMPA was found to abrogate gp120IIIB-induced toxicity in a dose-dependent manner. Additionally, 2-PMPA was neuroprotective when applied up to 2 h after the application of gp120IIIB. The abrogation of apoptosis by 2-PMPA was reversed with administration of mGlu3 receptor antagonists and with antibodies to transforming growth factor (TGF)-β. Further, consistent with the localization of GCP II, 2-PMPA failed to provide neuroprotection in the absence of glia. GCP II activity and its inhibition by 2-PMPA were confirmed in the hippocampal cultures using radiolabeled NAAG and high-performance liquid chromatography (HPLC) analysis. Taken together, these data suggest that GCP II is involved in mediating gp120-induced apoptosis in hippocampal neurons and GCP II inhibitors may have potential in the treatment of neuronal injury related to AIDS.

KW - GCP II

KW - Glutamate

KW - HIV-associated dementia

KW - Metabotropic glutamate receptors

KW - NAAG;TGF-β

UR - http://www.scopus.com/inward/record.url?scp=77649137126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649137126&partnerID=8YFLogxK

U2 - 10.3109/13550280903350598

DO - 10.3109/13550280903350598

M3 - Article

C2 - 19995130

AN - SCOPUS:77649137126

VL - 15

SP - 449

EP - 457

JO - Journal of NeuroVirology

JF - Journal of NeuroVirology

SN - 1355-0284

IS - 5-6

ER -